Retrospective, multicentric study to evaluate efficacy and safety of Nimotuzumab in cancer patients
Latest Information Update: 01 Apr 2019
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Cervical cancer; Glioma; Head and neck cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Biocon
- 03 Jan 2018 New trial record